Cefditoren in upper and lower community-acquired respiratory tract infections

Drug Design, Development and Therapy

Volumn , Issue 5, 2011, Pages 85-94

  Soriano, Francisco ^a   Giménez, María José ^a,b   Aguilar, Lorenzo ^a,b  

^a PRISM AG   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

Author keywords

Cefditoren; Community acquired respiratory tract infections; Haemophilus influenzae; Streptococcus pneumoniae; Streptococcus pyogenes

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFDITOREN; CEFDITOREN PIVOXIL; CEFUROXIME; PENICILLIN V; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIUM ISOLATE; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; LIPID DIET; LOWER RESPIRATORY TRACT INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; RECURRENT DISEASE; RELAPSE; REVIEW; SINGLE DRUG DOSE; SINUSITIS; STREPTOCOCCAL PHARYNGITIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; UPPER RESPIRATORY TRACT INFECTION; VAGINITIS; ANIMAL; COMMUNICABLE DISEASE; MICROBIOLOGY; RESPIRATORY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 79952957565     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S9499     Document Type: Review

References (71)

1. Mogyoros M. Challenges of managed care organisations in treating respiratory tract infections in an age of antibiotic resistance. Am J Man Care. 2001;7(Suppl 6):163-169.
2. Llor C. Consideraciones a la hora de la prescripción antibiótica en atención primaria. Med Clin Monogr (Barc). 2004;5:52-57.
3. Huovinen P, Cars O. Control of antimicrobial resistance: time for action. The essentials of control are already well known. BMJ. 1998; 317:613-614.
4. García-Rey C, Fenoll A, Aguilar L, Casal J. Effect of social and climatological factors on antimicrobial use and Streptococcus pneumoniae resistance in different provinces in Spain. J Antimicrob Chemother. 2004;54:465-471.
5. Granizo JJ, Aguilar L, Casal J, García-Rey C, Dal-Ré R, Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J Antimicrob Chemother. 2000;46:767-773.
6. García-Rey C, Aguilar L, Baquero F, Casal J, Dal-Ré R. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol. 2002;40:159-164.
7. Gómez J, Ruiz-Gómez J, Hernández-Cardona JL, Nuñez ML, Canteras M, Valdés M. Antibiotic resistance patterns of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a prospective study in Murcia, Spain, 1983-1992. Chemotherapy. 1994;40:299-303.
8. Granizo JJ, Aguilar L, Casal J, Dal-Ré R, Baquero F. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). J Antimicrob Chemother. 2000;46: 959-964.
9. García-Rey C, Aguilar L, Baquero F, Casal J, Martín JE. Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. J Clin Microbiol. 2002;40:2959-2963.
10. Pérez-Trallero E, García-de-la-Fuente C, García-Rey C, et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother. 2005;49:1965-1972.
11. Gómez-Lus R, Granizo JJ, Aguilar L, Bouza E, Gutierrez A, García- de-Lomas J. Is there an ecological relationship between rates of antibiotic resistance of species of the genus Streptococcus? The Spanish Surveillance Group for Respiratory Pathogens. J Clin Microbiol. 1999;37:3384-3386.
12. Richter SS, Heilmann KP, Beekmann SE, et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis. 2005;41:599-608.
13. Chan JC, Chu YW, Chu MY, Cheung TK, Lo JY. Epidemiological analysis of Streptococcus pyogenes infections in Hong Kong. Pathology. 2009;41:681-686.
14. Gracia M, Díaz C, Coronel P, et al. Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program. Diagn Microbiol Infect Dis. 2009;64:52-56.
15. Pérez-Trallero E, Martín-Herrero JE, Mazón A, et al. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). Antimicrob Agents Chemother. 2010;54:2953-2959.
16. Prieto J, Calvo A, Gómez-Lus ML. Antimicrobial resistance: a class effect? J Antimicrob Chemother. 2002;50(Suppl S2):7-12.
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA, USA; 2009.
18. Sahm DF, Brown NP, Thornsberry C, Jones ME. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med. 2008;120(3 Suppl 1):16-24.
19. Sahm DF, Brown NP, Draghi DC, Evangelista AT, Yee YC, Thornsberry C. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad Med. 2008;120(3 Suppl 1):8-15.
20. Jansen WT, Verel A, Beitsma M, Verhoef J, Milatovic D. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenzae. J Antimicrob Chemother. 2006;58:873-877.
21. Sevillano D, Giménez MJ, Cercenado E, et al. Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers. Antimicrob Agents Chemother. 2009;53:267-270.
22. Niki Y, Hanaki H, Matsumoto T, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens' antibacterial susceptibility. J Infect Chemother. 2009;15:156-167.
23. Sakata H, Toyonaga Y, Sato Y, et al. Nationwide survey of the development of drug-resistance in the pediatric field: drug sensitivity of Haemophilus influenzae in Japan. J Infect Chemother. 2009;15: 402-409.
24. Peric M, Bozdogan B, Jacobs MR, Appelbaum PC. Effects of an efflux echanism and ibosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother. 2003;47:1017-1022.
25. Cantón R, Unal S, Farrell DJ. Antibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients: PROTEKT years 1-5 (1999-2004). Int J Antimicrob Agents. 2007;30:546-550.
26. Darabi A, Hocquet D, Dowzicky MJ. Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial. Diagn Microbiol Infect Dis. 2010;67: 78-86.
27. Pérez-Trallero E, García-de-la-Fuente C, García-Rey C, et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother. 2005;49:1965-1972.
28. Fenoll A, Granizo JJ, Aguilar L, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009;47:1012-1020.
29. Fenoll A, Aguilar L, Granizo JJ, et al. Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae? J Antimicrob Chemother. 2008;62:1430-1433.
30. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
31. Fenoll A, Aguilar L, Giménez MJ, et al. Susceptibility of recently collected Spanish pneumococci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccine. Antimicrob Agents Chemother. 2010;54:2696-2698.
32. Fenoll A, Aguilar L, Vicioso MD, et al. Serotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in the current decade in Spain. Antimicrob Agents Chemother. 2010;54:5387-5390.
33. Picazo J, Ruiz-Contreras J, Casado-Flores J, et al. Relations between serotypes, age and clinical presentation of invasive pneumococcal disease in Madrid after the introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Clin Vaccine Immunol. 2011;18:89-94.
34. Pérez-Trallero E, Marimón JM, Ercibengoa M, Giménez MJ, Coronel P, Aguilar L. Antimicrobial susceptibilities of amoxycillin-non-susceptible and susceptible isolates among penicillin-non-susceptible Streptococcus pneumoniae. Clin Microbiol Infect. 2007;13:937-940.
35. Soriano F, Cafini F, Aguilar L, et al. Breakthrough in penicillin resistance? Streptococcus pneumoniae isolates with penicillin/cefotaxime MICs of 16 mg/L and their genotypic and geographical relatedness. J Antimicrob Chemother. 2008;62:1234-1240.
36. Rodríguez-Cerrato V, Gracia M, Del Prado G, et al. Antimicrobial susceptibility of multidrug-resistant Streptococcus pneumoniae strains with penicillin MICs of 8 to 32 mg/L. Diagn Microbiol Infect Dis. 2010;66:336-338.
37. Wellington K, Curran MP. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs. 2004;64:2597-2618.
38. Yamada M, Watanabe T, Miyara T, et al. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother. 2007;51:45-50.
39. Gracia M, Díaz C, Coronel P, et al. Antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight Central,East and Baltic European countries in 2005- 6: results of the Cefditoren Surveillance Study. J Antimicrob Chemother. 2008;61:1180-1181.
40. García-de-Lomas J, Lerma M, Cebrián L, et al. Influence of Haemophilus influenzae beta-lactamase production and/or ftsI gene mutations on in vitro activity of and susceptibility rates to aminopenicillins and second- and third-generation cephalosporins. Int J Antimicrob Agents. 2007;30:190-192.
41. Soriano F, Granizo JJ, Fenoll A, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patie nts: results from the cefditoren surveillance program. J Chemother. 2003;15: 107-112.
42. Soriano F, Coronel P, Gimeno M, Jiménez M, García-Corbeira P, Fernández-Roblas R. Inoculum effect and bactericidal activity of cefditoren and other antibiotics against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis. Eur J Clin Microbiol Infect Dis. 1996;15:761-763.
43. Sádaba B, Azanza JR, Quetglas EG, et al. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study. Rev Esp Quimioter. 2007;20:51-60.
44. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26: 1-10.
45. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160:1399-1408.
46. Granizo JJ, Sádaba B, Honorato J, et al. Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers. Int J Antimicrob Agents. 2008;31:396-398.
47. Moellering RC, Eliopoulos GM. Principles of anti-infective therapy. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett Principles and Practice of Infectious Diseases, 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005:242-253.
48. Cafini F, Yuste J, Giménez MJ, et al. Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model. PLoS One. 2010;5(8):e12041.
49. Sevillano D, Aguilar L, Alou L, et al. High protein binding and cidal activity against penicillin-resistant S. pneumoniae: a cefditoren in vitro pharmacodynamic simulation. PLoS One. 2008;3(7):e2717.
50. Karlowsky JA, Jones ME, Draghi DC, Critchley IA, Thornsberry C, Sahm DF. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. Diagn Microbiol Infect Dis. 2002;42:59-64.
51. Johnson DM, Biedenbach DJ, Beach ML, Pfaller MA, Jones RN. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis. 2000;37:99-105.
52. Jones RN, Biedenbach DJ, Croco MA, Barrett MS. In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 1998;31:573-578.
53. Agencia Española de Medicamentos y Productos Sanitarios. https:// sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm.
54. Food and Drug Administration. Spectracef prescribing information. http://www.crtx.com/docs/spectracef.pdf.
55. Weinberger DM, Dagan R, Givon-Lavi N, et al. Epidemiologic evidence for serotype- pecific acquired immunity to pneumococcal carriage. J Infect Dis. 2008;197:1511-1518.
56. Soininen A, Pursiainen H, Kilpi T, Käyhty H. Natural development of antibodies to pneumococcal capsular polysaccharides depends on the serotype: association with pneumococcal carriage and acute otitis media in young children. J Infect Dis. 2001;184:569-576.
57. Felmingham D, Robbins MJ, Ghosh G, et al. An in vitro characterization of cefditoren, a new ral cephalosporin. Drugs Exp Clin Res. 1994;20: 127-147.
58. Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. Efficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trials. Rev Esp Quimioter. 2008;21:14-21.
59. Ozaki T, Nishimura N, Suzuki M, et al. Five-day oral cefditoren pivoxil versus 10-day oral amoxicillin for pediatric group A streptococcal pharyngotonsillitis. J Infect Chemother. 2008;14:213-218.
60. Kikuta H, Shibata M, Nakata S, et al. Comparative study of 5-day and 10-day cefditoren pivoxil treatments for recurrent group Abeta-hemolytic Streptococcus pharyngitis in children. Int J Pediatr. 2009:863608.
61. Poachanukoon O, Kitcharoensakkul M. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigatorblinded, controlled trial. Clin Ther. 2008;30:1870-1879.
62. Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratorytract infections, with a focus on the per- athogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin Ther. 2006; 28:2061-2069.
63. Casey JR, Pichichero ME. The evidence base for cephalosporin superiority over penicillin in streptococcal pharyngitis. Diagn Microbiol Infect Dis. 2007;57(3 Suppl):S39-S45.
64. Budhani RK, Struthers JK. Interaction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of beta-lactamase-producing moraxellae by use of a continuousculture biofilm system. Antimicrob Agents Chemother. 1998;42: 2521-2526.
65. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. Clin Infect Dis. 2004;38:1526-1534.
66. Sevillano D, Aguilar L, Alou L, et al. Beta-lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics. PLoS One. 2008;3(12):e3846.
67. Alvarez-Sala JL, Kardos P, Martínez-Beltrán J, Coronel P, Aguilar L. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother. 2006;50:1762-1767.
68. Granizo JJ, Aguilar L, Gimenez MJ, Coronel P, Gimeno M, Prieto J. Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections. Rev Esp Quimioter. 2009;22:57-61.
69. Almirante B, Campos J, Cantón R, et al. Prudent use of antimicrobials: have we done the best we can? The SEIMC and REIPI statement. Enferm Infecc Microbiol Clin. 2010;28:485-486.
70. Baquero F, Garau J. Prudent use of antimicrobial agents: revisiting concepts and estimating erspectives in a global world. Enferm Infecc Microbiol Clin. 2010;28:487-488.
71. Daneman N, Low DE, McGeer A, Green KA, Fisman DN. At the threshold: defining clinically meaningful resistance thresholds forantibiotic choice in community-acquired pneumonia. Clin Infect Dis. 2008;46:1131-1138.